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1 |  INTRODUCTION
Gorlin syndrome is a genetic multisystemic disorder; it is also 
called Basal Cell Nevus Syndrome (BCNS, MIM #109400). 
It has a prevalence of 1/50.000, both sexes are equally af-
fected. The syndrome has an autosomal dominant inheritance, 
with a high penetrance and a variable expressivity (Reinders 
et al., 2018; Witmanowski, Szychta, Btochowiak, Jundzitt, 
& Czajkowski, 2017). The primary cause of the disease is a 
heterozygous mutation in the onco‐suppressor gene PTCH1 
(protein patched homolog 1, MIM* 601309). Many types of 
mutations can lead to the syndrome, including frameshift, 
missense, nonsense, and splicing mutations. Other genes 
that can cause the disease are SUFU (MIM* 607035) and 
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Abstract
Background: Gorlin syndrome, also known as basal cell nevus syndrome (BCNS), 
is a rare autosomal dominant genetic condition, characterized by the presence of 
multiple basal cell carcinomas at a young age, odontogenic keratocysts, skeletal 
anomalies, macrocephaly, and dysmorphisms. BCNS is mainly caused by mutations 
in PTCH1, an onco‐suppressor gene that maps at 9q22.3 region. A disease related 
to BCNS is the 9q22.3 microdeletion syndrome. This condition has an overlapping 
clinical phenotype with the BCNS, but it can present in addition: metopic craniosyn-
ostosis, overgrowth, obstructive hydrocephalus, developmental delay, intellectual 
disability, and seizures. This syndrome is caused by the deletion of a genomic region 
containing the PTCH1 and the FANCC.
Methods and Results: We report the case of an 11‐year‐old girl that came to our 
attention for overgrowth, dysmorphic features of the face, and craniosynostosis, but 
with a normal intellectual and motor development. At first we performed an array‐
comparative genomic hybridization (aCGH) analysis. The analysis showed no copy 
number changes. Then, we performed the analysis of the PTCH1 by next‐generation 
sequencing. This analysis showed a heterozygous frameshift mutation.
Conclusion: This is the first case with a PTCH1 point mutation with a 9q22.3 micro-
deletion syndrome phenotype. This finding may strengthen the importance of the role 
of the PTCH1, especially regarding the metopic craniosynostosis.
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less commonly PTCH2 (MIM* 603673). Those genes are 
involved in the sonic hedgehog pathway. In the 30% of the 
patients, there is no family history while the 70% has at least 
one first‐degree relative with the BCNS (Evans et al., 2017). 
The syndrome owes its name to the presence of multiple 
basal cell carcinomas. The main age of onset of those tumors 
is 25 years of age, the number of them can be variable, from 
a few to thousands. Many systems can be involved, such as 
the skeletal (bifid, fused or missing ribs, congenital vertebral 
anomalies, kyphoscoliosis), the stomatologic system (kera-
tocystic odontogenic tumors, dental ectopy, and agenesis), 
the central nervous system (calcification of the falx cerebri, 
congenital hydrocephalus, bridging of the sella turcica), and 
the ocular (cataract, coloboma, microphthalmia, strabismus). 
The phenotype of the patients with the syndrome is peculiar: 
they present hypertelorism, broad nasal bridge, frontal boss-
ing, palmar/plantar pits, and macrocephaly. Furthermore, 
the patients affected by BCNS have an incremented risk to 
develop various types of tumors (medulloblastoma, ovarian, 
and cardiac fibromas; Evans et al., 2017; Şereflican et al., 
2017; Witmanowski et al., 2017). The 9q22.3 microdeletion 
syndrome is a disease related to BCNS. It is a contiguous 
gene deletion syndrome, and the main genes involved in the 
condition are PTCH1 and FANCC (MIM* 613899). The clin-
ical manifestations are similar to those of BCNS; additional 
features that can be found in the syndrome, and not in BCNS 
are: metopic craniosynostosis, obstructive hydrocephalus, 
macrosomia, and intellectual disability (Muller et al., 2012; 
Reichert et al., 2015).
2 |  CLINICAL REPORT
Our case is an 11‐year‐old girl, with a silent family history 
and non‐consanguineous parents. Her pregnancy was normal, 
she was born at 41 weeks of gestational age by a C‐section. 
Her birth weight was 4.880 kg (>97°), her height was 57 cm 
(>97°), and her parents reported that the occipital‐frontal 
circumference was also >97°. At the age of 1  month, she 
was diagnosed with the craniosynostosis of all sutures, she 
underwent surgery at the age of 7 months. At 2 years of age, 
she was diagnosed with right vesicoureteral reflux, while the 
renal function was normal. When she was 6 years old, she 
started to present several jaw keratocysts, confirmed by his-
tological examination. An orthopedic evaluation revealed a 
calcaneo‐navicular synostosis and a spinal X‐ray showed a 
vertebral schisis of the posterior arches of C7 and T1 and 
a transverse mega‐apophysis of C7. We evaluated the girl 
when she was 9  years old. Physical examination showed 
macrocephaly, a wide forehead, hypertelorism, saddle nose, 
and small mouth (Figure 1). Her weight was 54  kg (>97° 
centile), her height was 153.5 cm (>97° centile), and her oc-
cipital‐frontal circumference was 57.8 cm (>97°centile).
3 |  RESULTS OF GENETIC 
TESTING
The first diagnostic hypothesis was the 9q22.3 microde-
letion syndrome, due to the presence of craniosynostosis 
and overgrowth associated with jaw keratocysts. The pres-
ence of craniosynostosis had already been investigated 
through the analysis of the FGFR3 and the FGFR2, the 
result was normal. In order to confirm this hypothesis, 
an array‐comparative genomic hybridization (aCGH) 
was performed using a 180‐mer oligonucleotide probes 
technology (SurePrint G3 Human CGH 4x180K, Agilent 
Technologies) according to the manufacture's instruction. 
Raw data were generated using Agilent Feature Extraction 
and analyzed by Cytogenomics 3.0.4.1 using ADM‐2 al-
gorithm (Agilent Technologies). To improve the accuracy 
of the results, the Diploid Peak Centralization algorithm 
was applied. The aberration filter was set to detect a min-
imum number of five consecutive probes/region and the 
minimum absolute average log ratio (MAALR) was ±0,25. 
F I G U R E  1  Photographs of the patient when she was 11 years 
old. Note, macrocephaly, big forehead, hypertelorism, saddle nose, and 
small mouth
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A second analysis was run with a MAALR of ±0,15 and 
with a minimum number of five probes/region to detect 
low level mosaicism. Copy number variations were not re-
ported if they coincided with the published DNA variants 
listed in the Database of Genomic Variants (http://proje 
cts.tcag.ca/varia tion/). Genomic coordinates are accord-
ing to the 37 build (March 2009) of the Human Genome 
Reference consortium (GRch37/hg19). Unexpectedly, the 
result of the analysis was normal. The other diagnostic 
hypothesis was Gorlin syndrome. This is the reason why 
the analysis of the PTCH1 by next‐generation sequencing 
was performed. This analysis showed a c.1502A duplica-
tion in exon 6. This variation causes a frameshift muta-
tion p.(Val502Glyfs*13), that leads to the formation of a 
premature stop codon. This mutation has never been re-
ported in literature, but mutations in the same region have 
been described as pathogenetic variants. We could not per-
form the segregation study because the parents denied the 
consent.
4 |  DISCUSSION
In literature, many cases of PTCH1 mutations are de-
scribed, and they have always been related to Gorlin 
syndrome. PTCH1 is the first gene that clinicians ana-
lyze when the phenotype of the patient is consistent with 
BCNS: macrocephaly, jaw keratocysts, multiple basal car-
cinomas, and so on (Evans et al., 2017; Witmanowski et 
al., 2017). The syndrome has never been associated with 
craniosynostosis and overgrowth. This is the reason why 
our first diagnostic hypothesis was the 9q22.3 microdele-
tion syndrome. Those characteristics are indeed very well 
described in the 9q22.3 microdeletion syndrome (Muller 
et al., 2012; Reichert et al., 2015). This is the first case 
of a patient with a PTCH1 point mutation and a 9q22.3 
microdeletion syndrome phenotype (Table 1). At protein 
level, we hypothesized that the identified mutation can 
lead to the formation of a truncated protein without several 
domains. In particular, the predicted effect of mutation at 
protein level (p.(Val502Glyfs*13)) suggests that the sterol‐
sensing domain (426‐616aa) is lacking. Functional studies 
of the variation show an alteration of the splicing. Those 
findings lead us to think that this mutation is pathogenetic. 
Conversely, the reported point mutations of PTCH1, as-
sociated with Gorlin phenotype, are in general localized 
in the second half of the gene, preserving the sterol‐sens-
ing domain. This domain is important to sterol regulatory 
element‐binding protein (SREBP) cleavage activation. We 
can hypothesize that this domain can influence the correct 
cranial development and that the formation of the protein 
without this domain or the mRNA decay leading to a com-
plete haploinsufficiency might favor additional phenotypic 
features such as the craniosynostosis, reported in the 9q22.3 
deletion syndrome. Further studies are needed to prove this 
connection. Anyway, this finding may strengthen the im-
portance of the role of the PTCH1, especially regarding the 
syndromic craniosynostosis.
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  Gorlin syndrome 9q22.3 deletion Our patient
Multiple basal cell carcinomas + + −
Odontogenic keratocyst + + +
Skeletal anomalies + + +
Palmoplantar pits + + −
Calcification of the falx cerebri + + −
Macrocephaly + + +
Frontal bossing + + +
Macrosomia − + +
Metopic craniosynostosis − + +
Obstructive hydrocephalus − + −
Intellectual disability − + −
T A B L E  1  Summary of the features of Gorlin syndrome and 9q22.3 deletion syndrome
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